Considering the side effect of laser treatment and the “simple” method of anti-VEGF intravitreal administration, experienced ophthalmologists tend to frequently apply anti-VEGF to type-1 and threshold ROP patients. The gene discussed is VEGFA; the disease is retinopathy of prematurity.